Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.

In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59-0.94) instead of the correct HR of 0.77 (95% CI 0.62-0.94). In addition, the HRs of the secondary composite cardiovascular outcome were incorrectly reported as 0.88 (95% CI 0.71-1.09) for no insulin at baseline and 0.83 (95% CI 0.69-1.01) for insulin at baseline (P for interaction 0.70). The correct HRs for the secondary composite cardiovascular outcome are 0.95 (95% CI 0.74-1.23) for no insulin at baseline and 0.82 (95% CI 0.69-0.97) for insulin at baseline (P for interaction 0.33). The authors apologize for the error. The online version of the article (https://doi.org/10.2337/dc21-1944) has been updated to correct the error.